Emmaus Life Sciences Q1 2025 net loss narrows to $2.3M; revenue flat at $2.4M

Emmaus Life Sciences, Inc.

2025-Q1 EPS reported -$0.04 revenue$2,406,000

Net loss $2.3M ($0.04/sh) improved from $4.3M loss YoY; operating loss narrowed to $1.0M.
Net revenue $2.4M, down slightly from $2.5M YoY due to generic L-Glutamine competition.
Total operating expenses fell to $3.2M from $5.0M, mainly from workforce reduction in Q4 2024.
Cash and equivalents $1.3M at March 31, 2025, comparable to $1.4M at Dec 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.